Vertex Pharmaceuticals Maps Growth Beyond CF at Cantor Conference

Key Points

• Interested in Vertex Pharmaceuticals Incorporated? Here are five stocks we like better.

• Vertex is broadening beyond cystic fibrosis through its Crinetics acquisition, adding PALSONIFY and the late-stage congenital adrenal hyperplasia drug atumelnant, which the company estimates could generate a combined $5 billion in peak sales.

• Renal pipeline catalysts are approaching: povetacicept has a November 30 FDA decision date for IgA nephropathy, while Phase II data for inaxaplin are expected before year-end and its Phase III interim analysis is planned for early 2027.

• JOURNAVX is becoming a major commercial growth driver as insurance coverage and Vertex’s sales force expand; the company is targeting a tripling of prescriptions in 2026 versus 2025. Phase III diabetic peripheral neuropathy studies of suzetrigine are expected to finish enrollment by year-end.

Vertex Pharmaceuticals (NASDAQ:VRTX) outlined a broadening commercial and clinical strategy at the Cantor Global Healthcare Conference, highlighting its recent Crinetics acquisition, planned renal product launch efforts and upcoming pipeline milestones across kidney disease, pain, cystic fibrosis and rare endocrine disorders.

Susie Lisa, Vertex’s senior vice president of investor relations, said the company evaluates internal programs and acquisitions through a research-and-development framework focused on causal human biology, validated biomarkers, specialty markets and streamlined regulatory pathways. She said the company pursues assets that either accelerate existing programs or establish a presence in selected disease areas.

→ 3 Lesser-Known Quantum Plays the Market May Be Overlooking Right Now

Lisa said Vertex completed its acquisition of Crinetics last week, adding PALSONIFY, which is being launched for acromegaly, and the late-stage congenital adrenal hyperplasia candidate atumelnant. She described rare specialty endocrinology as an area with relatively de-risked development because measurements in Phase II trials can carry through to Phase III studies.

Renal Pipeline Milestones

Vertex expects a November 30 PDUFA date for povetacicept in immunoglobulin A nephropathy, or IgAN. Lisa said the company’s interactions with the FDA’s renal division have been constructive and that the application remains on track.

→ Qualcomm’s Data Center Bet Looks More Real After Amazon’s AI Deal

Lisa argued that povetacicept is differentiated by its 52% reduction in urine protein-to-creatinine ratio at 36 weeks, along with hematuria resolution, reductions in galactose-deficient IgA1 and its ability to help patients reach KDIGO guideline levels. She also cited the drug’s monthly autoinjector administration and low-volume dose as potential advantages over competitors’ dosing regimens.

Vertex is also advancing povetacicept in primary membranous nephropathy, where it is in the Phase II/III portion of a 104-week study, and in a Phase II study for myasthenia gravis. The company continues to evaluate RUBY-4 data in warm autoimmune hemolytic anemia.

→ Defense, Solar, and Refining Stocks Split as the Iran Conflict Raises Energy Risk

For inaxaplin, Vertex expects Phase II proof-of-concept data from the AMPLIFIED population-expansion study before year-end. The study includes roughly 50 patients with two APOL1 alleles, including patients with more modest proteinuria and others with heavier proteinuria and Type 2 diabetes. Lisa said the Phase III AMPLITUDE study remains on track to complete enrollment by year-end, with an interim analysis expected in early 2027.

The AMPLITUDE interim analysis will use eGFR slope versus placebo as its primary endpoint. Lisa said patients in the study experience eGFR decline at nearly twice the rate of traditional kidney-disease patients, which could make a treatment difference observable at 48 weeks.

Commercial Expansion Beyond Cystic Fibrosis

Lisa said Vertex has expanded its commercial infrastructure substantially from its prior focus on cystic fibrosis. The company built separate sales and support capabilities for CASGEVY, including support for treatment centers, patients and families, and has also expanded its acute-pain organization for JOURNAVX.

Vertex initially launched JOURNAVX with roughly 100 field representatives and increased the field force to about 150 before doubling it earlier this year as reimbursed access expanded, Lisa said. The company had 260 million covered lives as of early August, she added.

According to Lisa, JOURNAVX prescription growth has been supported by physician and patient feedback, broader insurance access, field-force expansion, marketing activity and outreach to a wide range of prescribers, including emergency and trauma clinicians, anesthesiologists, orthopedic surgeons, obstetricians, dentists and plastic surgeons.

The company is targeting a tripling of JOURNAVX prescriptions in 2026 compared with 2025, Lisa said. She noted that the acute-pain market remains large, with 80 million Americans receiving a prescription annually. Vertex recently appointed Jasper van Grunsven as executive vice president to focus on the pain franchise and newer products.

Chronic Pain and Endocrinology Programs

Vertex expects to complete enrollment in two Phase III studies of suzetrigine in diabetic peripheral neuropathy by year-end. Lisa said both studies are 12 weeks long, with data potentially available by mid-2027. One study includes about 1,100 patients and compares suzetrigine with placebo and pregabalin, while the other includes about 700 patients and compares the drug with placebo.

The company has focused the studies on experienced diabetic peripheral neuropathy trial sites in an effort to better manage placebo effects, Lisa said. Vertex is also evaluating combinations targeting NaV1.7 and NaV1.8 sodium channels for potential use in acute and chronic pain.

Manisha Pai, Vertex’s executive director of investor relations, said a move into musculoskeletal pain could require a commercial partner because it would involve a primary-care market. However, she said the company believes acute pain and peripheral neuropathic pain can be addressed through a specialty commercial model.

On the Crinetics portfolio, Pai said Vertex sees potential for $5 billion in peak sales from PALSONIFY and atumelnant combined, with PALSONIFY potentially reaching blockbuster status and atumelnant representing a multibillion-dollar opportunity. Atumelnant is in Phase III development for congenital adrenal hyperplasia.

Pai said Vertex is still reviewing timelines and financial details following the transaction’s closing and expects to provide updated accounting and financial information on its third-quarter earnings call. She said the company remains confident in atumelnant’s Phase II safety profile after a liver-enzyme elevation observed in one patient was reversible and was not accompanied by bilirubin elevation or clinical consequences.

About Vertex Pharmaceuticals (NASDAQ:VRTX)

Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company combines research in human genetics with drug discovery and development.

Vertex is best known for its cystic fibrosis portfolio, which includes CFTR modulator therapies such as Kalydeco, Orkambi, Symdeko and the combination marketed as Trikafta in the United States and Kaftrio in other markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

The article “Vertex Pharmaceuticals Maps Growth Beyond CF at Cantor Conference” was originally published by MarketBeat.

View MarketBeat’s top stocks for September 2026.